semaglutide mash approval CDSCO Clears Wegovy for — India's First GLP-1 for Liver Disease, India's drug regulator CDSCO approved Novo Nordisk's Wegovy (semaglutide 2.4mg) on 17 July 2026 for MASH, based on FDA Approves Semaglutide to Treat

Research suggests several beneficial mechanisms: Improved insulin sensitivity : Insulin resistance is a key driver of PCOS symptoms, and GLP-1 medications can enhance insulin action Weight loss effects : Even modest weight reduction (510% of body weight) can restore ovulation and regular cycles in women with PCOS [17] [18] Reduced androgen levels : Weight loss and improved insulin sensitivity often lead to decreased testosterone and other androgens Restoration of ovulation : Some women with PCOS who previously had absent periods may begin ovulating regularly NICE Clinical Knowledge Summary on PCOS recommends lifestyle modification and weight loss as first-line interventions for overweight women with the condition

Y Time Published Y I recommend this product

This corresponds to a 2-month supply

"This supports more individualized counseling and surveillance rather than a generic message that weight loss itself inevitably causes hair loss," he said

Glucose-6-Phosphate Dehydrogenase Deficiency and Primaquine Hemolytic Toxicity